Clinical trials: Liver Metastases of Colorectal Cancer
Colorectal Cancer, Resectable Liver Metastasis
Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis
This study aims to discuss the efficacy and safety of neoadjuvant chemotherapy with XELOX regimen (oxaliplatin plus capecitabine) .
- Trial name
- NCT00630045
- Testing
- neoadjuvant chemotherapy with oxaliplatin and capecitabine, resection of liver metastasis
- Where
- 2 sites in China
- Volunteers
- 392 people
- Sponsor
- Peking University People's Hospital
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer
This single arm study will assess the resection rate of liver metastasis, time to disease progression, and safety of neoadjuvant treatment with Avastin in combination with oxaliplatin and capecitabine (XELOX) in patients with…
- Trial name
- NCT00700570
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin
- Where
- 6 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Metastasis to Liver, Colorectal Cancer
Comparison of Image Quality Between "Double Low Dose" Liver CT and Standard Liver CT
In patients with malignancies, contrast-enhanced abdominal CT (hereafter abdominal CT) plays an important role in detecting carcinoma recurrence and assessing treatment response.
- Trial name
- NCT05790590
- Testing
- Double low dose CT, Standard dose CT
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Seoul National University Hospital
Colorectal Cancer, Liver Metastases
Carcinoembryonic Antigen-loaded Dendritic Cells in Advanced Colorectal Cancer Patients
Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system. As such they are currently used in clinical vaccination protocols in cancer patients.
- Trial name
- NCT00228189
- Testing
- CEA-loaded dendritic cell vaccine
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Colo-rectal Cancer, Liver Metastases
Radiogenomic Profiling of Dendritic Cells and Macrophages to Predict Recurrence in Colorectal Liver Metastasis
The RaP-DMac-LiMe study (Radiogenomic Profiling of Dendritic Cells and Macrophages to Predict Recurrence in Colorectal Liver Metastasis) is a monocentric, non-profit observational study promoted by Fondazione Policlinico…
- Conditions
- Colo-rectal Cancer, Liver Metastases, Colon Cancer
- Trial name
- RaP-DMac-LiMe (NCT07744139)
- Testing
- Radiogenomic and Immune Profiling, Prospective Radiogenomic and ctDNA Profiling
- Volunteers
- 210 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Colorectal Cancer, Neoplasm Metastasis
Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases
Primary Objective: This trial is elaborating a model for rapidly predicting (day 21) the response to monoclonal antibodies anti-EGFR and anti-VEGF (cetuximab and bevacizumab) based on biological markers and/or functional imaging.
- Trial name
- NCT00327093
- Testing
- cetuximab, bevacizumab
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Hospices Civils de Lyon
Colorectal Cancer, Immunotherapy
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
Colorectal cancer (CRC) is a significant cause of morbidity and mortality worldwide. Its early clinical manifestations are often subtle, leading to late-stage diagnosis in about 30% of cases with distant metastases.
- Conditions
- Colorectal Cancer, Immunotherapy, Radiotherapy, Targeted Therapy
- Trial name
- NCT06356584
- Testing
- Immunotherapy (Sintilimab), Targeted Therapy Agent (Fruquintinib), Radiotherapy (SBRT and LDRT)
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Shandong Cancer Hospital and Institute
Liver Metastasis, Colorectal Neoplasms
Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases
The purpose of this study is to determine whether the Litx™ system is safe and effective in combination with chemotherapy in the treatment of liver metastasis arising from colorectal cancer.
- Conditions
- Liver Metastasis, Colorectal Neoplasms, Liver Neoplasms, Neoplasm Metastasis
- Trial name
- NCT00083785
- Testing
- Talaporfin sodium (LS11), LED-based light infusion device, Light emitting diodes (LED)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Light Sciences LLC
Colorectal Cancer
Eicosapentaenoic Acid (EPA) for Treatment of Colorectal Cancer Liver Metastases
Eicosapentaenoic acid (EPA) is a naturally occuring omega-3 polyunsaturated fatty acid found in oily fish. EPA has anti-colorectal (bowel) cancer activity in experimental models.
- Trial name
- EMT (NCT01070355)
- Testing
- Eicosapentaenoic acid free fatty acid
- Where
- United Kingdom
- Volunteers
- 88 people
- Sponsor
- University of Leeds
Colorectal Cancer, Metastatic Cancer
Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver
RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with surgery may kill more tumor cells.
- Trial name
- NCT00030563
- Testing
- irinotecan hydrochloride, adjuvant therapy, conventional surgery
- Where
- 3 sites in United States, Canada
- Sponsor
- University of Washington
Colorectal Cancer, Liver Metastases
French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies.
- Conditions
- Colorectal Cancer, Liver Metastases, Stage IV Colorectal Cancer, Minimal Residual Disease
- Trial name
- NCT06287723
- Testing
- Blood sample/Liquid biopsy
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Montpellier
Colorectal Cancer Metastatic
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
Microdevices have been used to ascertain in vivo drug response, which can lead to improved cancer treatment delivery; however, they have not been evaluated for liver tumors.
- Trial name
- NCT07193862
- Testing
- Doxorubicin, FOLFOX, Botensilimab, Balstilimab, Bevacizumab, FOLFIRI, FOLFIRINOX, AGEN2373
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Northwell Health
Colorectal Cancer
Minimally Invasive Simultaneous Colorectal and Liver Surgery
Up to 25% of newly diagnosed patients with colorectal cancer (CRC) have liver metastases (LM). Simultaneous colorectal and hepatic resection has been proven to be a safe and effective approach in dealing with metastatic…
- Trial name
- NCT03551470
- Testing
- Robotic one-stage colorectal and liver resection
- Where
- Italy
- Volunteers
- 22 people
- Sponsor
- Azienda Ospedaliera San Giovanni Battista
Colorectal Cancer, Metastatic Cancer
Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab and bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00438737
- Testing
- bevacizumab, cetuximab, fluorouracil
- Where
- France
- Volunteers
- 100 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colorectal Cancer Metastatic
A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
This is a phase I, open-label clinical study of T3011 in combination with Toraplizumab and Regorafenib in patients with liver metastases from colorectal cancer.
- Trial name
- NCT06283303
- Testing
- T3011 hepatic artery infusion, toripalimab, regorafenib
- Volunteers
- 8 people
- Sponsor
- China Medical University, China
Breast Cancer, Colon Cancer
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
This pilot clinical trial studies copper Cu 64 anti-carcinoembryonic antigen (CEA) monoclonal antibody M5A positron emission tomography (PET) in diagnosing patients with CEA positive cancer.
- Conditions
- Breast Cancer, Colon Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT02293954
- Testing
- radionuclide imaging, positron emission tomography, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.
This 2 arm study will compare the resection rate of liver metastases and safety of surgery in patients with metastatic colorectal cancer and primarily unresectable liver metastases receiving treatment with Avastin in combination…
- Trial name
- NCT00778102
- Testing
- 5-FU, Irinotecan, Leucovorin
- Where
- 19 sites in Austria, France and 2 more
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer, Metastatic Cancer
Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as floxuridine, dexamethasone, and irinotecan, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003753
- Testing
- dexamethasone, floxuridine, irinotecan hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Colorectal Cancer
Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases
The goal of this clinical trial is to evaluate the superiority of ivonescimab combined with FOLFIRI over FOLFIRI + bevacizumab as second-line treatment of non resectable pMMR/MSS BRAFwt mCRC patients without liver metastases in…
- Trial name
- COLIBRI-GI (NCT07359456)
- Testing
- Ivonescimab, Bevacizumab, FOLFIRI Protocol
- Where
- 22 sites in France
- Volunteers
- 130 people
- Sponsor
- UNICANCER
Colorectal Cancer, Metastatic Cancer
Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00408772
- Testing
- bevacizumab, capecitabine, oxaliplatin
- Where
- United States
- Sponsor
- University of California, Davis